Dosage of enoxaparin among obese and renal impairment patients

Thrombosis Research

Volumn 116, Issue 1, 2005, Pages 41-50

  Bazinet, Annie ^a,b   Almanric, Karine ^a,b   Brunet, Catherine ^a,b   Turcotte, Isabel ^a,b   Martineau, Josée ^a   Caron, Stéphanie ^a   Blais, Normand ^a   Lalonde, Lyne ^a,b,c  

^a Cite de la Sante de Laval   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Research Team in Primary Care   (Canada)

Author keywords

Anti Xa activity; Anticoagulant; Impaired renal function; Low molecular weight heparin; Obesity

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBODY; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A ANTIBODY; CLOPIDOGREL; CREATININE; ENOXAPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; BODY MASS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIALYSIS; DOSE RESPONSE; FEMALE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; RISK ASSESSMENT; SAMPLE SIZE; THROMBOSIS; TIME SERIES ANALYSIS;

EID: 17444425341     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.10.004     Document Type: Article

References (41)

1. J.I. Weitz Low-molecular-weight heparin N. Engl. J. Med. 337 10 1997 688 698
2. J. Hirsh, T.E. Warkentin, S.G. Shaughnessy, S.S. Anand, J.L. Halperin, and R. Raschke Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety Chest 119 1 Suppl. 2001 64S 94S
3. L. Houbouyan, B. Boutiere, G. Contant, M.D. Dautzenberg, P. Fievet, and G. Potron Validation protocol of analytical hemostasis systems: measurement of anti-Xa activity of low-molecular-weight heparins Clin. Chem. 42 8 Pt.1 1996 1223 1230
4. Aventis Pharma Inc. Monographie de Lovenox (énoxaparine sodique). 14 février 2003.
5. Aventis Pharma Inc. Monographie de Lovenox (énoxaparine sodique). 20 avril 2001.
6. J. Nagge, M. Crowther, and J. Hirsh Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch. Intern. Med. 162 22 2002 2605 2609
7. J.S. Hulot, C. Vantelon, S. Urien, A. Bouzamondo, I. Mahe, and A. Ankri Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment Ther. Drug Monit. 26 3 2004 305 310
8. P. Mismetti, S. Laporte-Simitsidis, C. Navarro, P. Sie, P. d'Azemar, and J. Necciari Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin) Thromb. Haemost. 79 6 1998 1162 1165
9. J.P. Collet, G. Montalescot, R. Choussat, L. Lison, and A. Ankri Enoxaparin in unstable angina patients with renal failure Int. J. Cardiol. 80 1 2001 81 82
10. G.J. Sanderink, C.G. Guimart, M.L. Ozoux, N.U. Jariwala, U.A. Shukla, and B.X. Boutouyrie Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment Thromb. Res. 105 3 2002 225 231
11. B.A. Duplaga, C.W. Rivers, and E. Nutescu Dosing and monitoring of low-molecular-weight heparins in special populations Pharmacotherapy 21 2 2001 218 234
12. R.C. Becker, F.A. Spencer, M. Gibson, J.E. Rush, G. Sanderink, and S.A. Murphy Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes Am. Heart J. 143 2002 753 759
13. D.F. Brophy, L.D. Wazny, T.W. Gehr, T.J. Comstock, and J. Venitz The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease Pharmacotherapy 21 2 2001 169 174
14. Y. Cadroy, J. Pourrat, M.F. Baladre, S. Saivin, G. Houin, and J.L. Montastruc Delayed elimination of enoxaparin in patients with chronic renal insufficiency Thromb. Res. 63 3 1991 385 390
15. J.Y. Yee, and S.B. Duffull The effect of body weight on dalteparin pharmacokinetics. A preliminary study Eur. J. Clin. Pharmacol. 56 4 2000 293 297
16. S.J. Wilson, K. Wilbur, E. Burton, and D.R. Anderson Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism Haemostasis 31 1 2001 42 48
17. J. Harenberg Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes J. Thromb. Haemost. 2 4 2004 547 550
18. M. Alhenc-Gelas, C. Jestin-LeGuernic, J.F. Vitoux, A. Kher, M. Aiach, and J.N. Fiessinger Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group Thromb. Haemost. 71 6 1994 698 702
19. M.N. Levine, A. Planes, J. Hirsh, M. Goodyear, N. Vochelle, and M. Gent The relationship between the antifactor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement Thromb. Haemost. 62 1989 940 944
20. D. Rosenbloom, and J.S. Ginsberg Arguments against monitoring levels of anti-factor Xa in conjunction with Low-Molecular-Weight-Heparin therapy Can. J. Hosp. Pharm. 55 2002 15 19
21. M. Laposata, D. Green, E.M. Van Cott, T.W. Barrowcliffe, S.H. Goodnight, and R.C. Sosolik College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban Arch. Pathol. Lab. Med. 122 1998 799 807
22. G. Agnelli, A. Iorio, C. Renga, E. Boschetti, G.G. Nenci, and F.A. Ofosu Prolonged antithrombin activity of low-molecular-weight heparins Circulation 92 1995 2819 2824
23. G.F. Handeland, U. Abildgaard, H.A. Holm, and K.E. Arnesen Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin Eur. J. Clin. Pharmacol. 39 2 1990 107 112
24. G. Simonneau, B. Charbonnier, H. Decousus, B. Planchon, J. Ninet, and P. Sie Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis Arch. Intern. Med. 153 13 1993 1541 1546
25. M. Holmström, M.C. Berglund, S. Granquist, G. Bratt, E. Törnebohm, and D. Lockner Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg Thromb. Res. 67 1 1992 49 55
26. P. Lindmarker, M. Holmstrom, S. Granqvist, H. Johnsson, and D. Lockner Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis Thromb. Haemost. 72 2 1994 186 190
27. E. Chiquette, M.G. Amato, and H.I. Bussey Comparison of anticoagulation clinic with usual medical care. Anticoagulation control, patient outcomes, and health care costs Arch. Intern. Med. 158 1998 1641 1647
28. M.E. Winter's Basic clinical pharmacokinetics 3e ed 1994 Applied Thepapeutic Vancouver
29. L. Shargel, and A.B.C. Yu Applied biopharmaceutics and pharmacokinetics 4e éd. 1999 Appleton & Lange Stamford
30. G.R. Aronoff Practical guidelines for drugs dosing in patients with renal impairment R.W. Schrier Manual of nephrology 5th ed. 2000 Lippincott Williams & Wilkins Philadelphia 182 202
31. D.W. Cockroft, and H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
32. P.S. Wells, M.A. Forgie, M. Simms, A. Greene, D. Touchie, and G. Lewis The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism Arch. Intern. Med. 163 8 2003 917 920
33. R.J. Beyth, L.M. Quinn, and C.S. Landefeld Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin Am. J. Med. 105 2 1998 91 99
34. J.W. Hainer, J.S. Barrett, C.A. Assaid, M.J. Fossler, D.S. Cox, and T. Leathers Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study Thromb. Haemost. 87 5 2002 817 823
35. C. Goudable, S. Saivin, G. Houin, P. Sie, B. Boneu, and H. Tonthat Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure Nephron 59 1991 543 545
36. V. Siguret, E. Pautas, M. Fevrier, C. Wipff, B. Durand-Gasselin, and M. Laurent Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days Thromb. Haemost. 84 5 2000 800 804
37. H. Bounameaux, and P. de Moerloose Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No J. Thromb. Haemost. 2 4 2004 551 554
38. M.K. Gould, A.D. Dembitzer, R.L. Doyle, T.J. Hastie, and A.M. Garber Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials Ann. Intern. Med. 130 10 1999 800 809
39. M. Cohen, C. Demers, E.P. Gurfinkel, A.G. Turpie, G.J. Fromell, and S. Goodman A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group N. Engl. J. Med. 337 7 1997 447 452
40. G. Merli, T.E. Spiro, C.G. Olsson, U. Abildgaard, B.L. Davidson, and A. Eldor Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease Ann. Intern. Med. 134 3 2001 191 202
41. J. Hirsh, and R. Raschke Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 3 Suppl. 2004 188S 203S